Free Trial
NASDAQ:TSVT

2seventy bio (TSVT) Stock Price, News & Analysis

2seventy bio logo
$5.00 0.00 (0.00%)
As of 05/13/2025

About 2seventy bio Stock (NASDAQ:TSVT)

Key Stats

Today's Range
$5.00
$5.00
50-Day Range
$4.98
$5.00
52-Week Range
$2.29
$5.30
Volume
N/A
Average Volume
641,794 shs
Market Capitalization
$266.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Hold

Company Overview

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

Receive TSVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 2seventy bio and its competitors with MarketBeat's FREE daily newsletter.

TSVT Stock News Headlines

Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.
2seventy Bio reports Q4 EPS (37c) vs ($1.11) last year
2seventy Bio price target lowered to $5 from $6 at Morgan Stanley
See More Headlines

TSVT Stock Analysis - Frequently Asked Questions

2seventy bio's stock was trading at $2.94 at the start of the year. Since then, TSVT stock has increased by 70.1% and is now trading at $5.00.
View the best growth stocks for 2025 here
.

2seventy bio, Inc. (NASDAQ:TSVT) posted its quarterly earnings results on Wednesday, May, 7th. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.11. The company earned $22.94 million during the quarter, compared to analysts' expectations of $13.96 million. 2seventy bio had a negative trailing twelve-month return on equity of 53.65% and a negative net margin of 207.25%.

Shares of TSVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that 2seventy bio investors own include Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Home Depot (HD), Meta Platforms (META) and NVIDIA (NVDA).

Company Calendar

Last Earnings
5/07/2025
Today
6/30/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TSVT
Fax
N/A
Employees
440
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
0.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$217.57 million
Net Margins
-207.25%
Pretax Margin
-207.25%

Debt

Sales & Book Value

Annual Sales
$48.37 million
Price / Cash Flow
N/A
Book Value
$5.04 per share
Price / Book
0.99

Miscellaneous

Free Float
47,874,000
Market Cap
$266.15 million
Optionable
Optionable
Beta
1.04
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:TSVT) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners